Beijing Strong Biotechnologies,Inc. (SHE:300406)
China · Delayed Price · Currency is CNY 11.65
-0.30 (-2.51%)
Jun 8, 2026, 3:04 PM CST
SHE:300406 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,358 | 1,343 | 1,648 | 1,737 | 1,508 | 1,598 |
Other Revenue | 12.96 | 12.96 | 11.28 | 4.4 | 2.88 | 1 |
| 1,371 | 1,356 | 1,659 | 1,742 | 1,511 | 1,599 | |
Revenue Growth (YoY) | -13.52% | -18.29% | -4.75% | 15.27% | -5.53% | 88.58% |
Cost of Revenue | 283.69 | 284.5 | 361.88 | 445.01 | 384.12 | 448.5 |
Gross Profit | 1,087 | 1,071 | 1,297 | 1,297 | 1,127 | 1,151 |
Selling, General & Admin | 405.35 | 408.88 | 457.67 | 491.04 | 457.36 | 444.38 |
Research & Development | 179.28 | 181.73 | 188.53 | 162.9 | 137.2 | 127.01 |
Other Operating Expenses | 20.41 | 17.88 | 15.45 | 14.97 | 12.85 | 12.92 |
Operating Expenses | 631.39 | 634.85 | 665.03 | 692.35 | 625.46 | 602.71 |
Operating Income | 455.43 | 436.16 | 632.01 | 604.27 | 501.29 | 548.17 |
Interest Expense | -49.94 | -49.44 | -47.61 | -46.99 | -52.64 | -21.59 |
Interest & Investment Income | 24.8 | 22.57 | 19.82 | 25.95 | 21.48 | 15.74 |
Currency Exchange Gain (Loss) | -1.45 | -1.45 | -0.1 | -0.12 | 2.21 | -0.29 |
Other Non Operating Income (Expenses) | 0.52 | -0.46 | 2.39 | -3.5 | -28.33 | -19.94 |
EBT Excluding Unusual Items | 429.36 | 407.38 | 606.52 | 579.62 | 444.01 | 522.09 |
Impairment of Goodwill | -174.77 | -174.77 | - | - | -3.03 | - |
Gain (Loss) on Sale of Investments | 0.15 | - | - | - | - | - |
Gain (Loss) on Sale of Assets | -2.2 | -2.87 | -2.11 | -3.5 | -2.68 | 0.16 |
Asset Writedown | -2.24 | -2.24 | -1.38 | -0.21 | -2.29 | -0.11 |
Other Unusual Items | 11.91 | 8.76 | 17.66 | 17.64 | 13.35 | 14.85 |
Pretax Income | 262.21 | 236.25 | 620.69 | 593.55 | 449.35 | 536.99 |
Income Tax Expense | 49.64 | 45.71 | 83.87 | 71.48 | 54.89 | 67.33 |
Earnings From Continuing Operations | 212.58 | 190.54 | 536.82 | 522.07 | 394.46 | 469.66 |
Minority Interest in Earnings | -0.35 | -0.66 | 1.47 | 1.67 | -5.37 | -64.01 |
Net Income | 212.22 | 189.87 | 538.29 | 523.74 | 389.1 | 405.65 |
Net Income to Common | 212.22 | 189.87 | 538.29 | 523.74 | 389.1 | 405.65 |
Net Income Growth | -57.63% | -64.73% | 2.78% | 34.60% | -4.08% | 261.30% |
Shares Outstanding (Basic) | 591 | 593 | 579 | 582 | 581 | 588 |
Shares Outstanding (Diluted) | 591 | 593 | 598 | 595 | 614 | 588 |
Shares Change (YoY) | -1.95% | -0.79% | 0.49% | -3.00% | 4.37% | 7.25% |
EPS (Basic) | 0.36 | 0.32 | 0.93 | 0.90 | 0.67 | 0.69 |
EPS (Diluted) | 0.36 | 0.32 | 0.90 | 0.88 | 0.67 | 0.69 |
EPS Growth | -56.79% | -64.44% | 2.27% | 31.47% | -2.99% | 236.88% |
Free Cash Flow | 558.46 | 525.87 | 546.36 | 437.06 | 299.69 | 275.9 |
Free Cash Flow Per Share | 0.94 | 0.89 | 0.91 | 0.73 | 0.49 | 0.47 |
Dividend Per Share | 0.700 | 0.700 | 0.400 | 0.200 | 0.100 | 0.100 |
Dividend Growth | 75.00% | 75.00% | 100.00% | 100.00% | - | 0.66% |
Gross Margin | 79.30% | 79.01% | 78.19% | 74.45% | 74.58% | 71.96% |
Operating Margin | 33.23% | 32.18% | 38.10% | 34.70% | 33.18% | 34.27% |
Profit Margin | 15.48% | 14.01% | 32.45% | 30.07% | 25.75% | 25.36% |
Free Cash Flow Margin | 40.75% | 38.80% | 32.93% | 25.09% | 19.84% | 17.25% |
EBITDA | 522.94 | 504.06 | 701.44 | 658.03 | 554.35 | 590.51 |
EBITDA Margin | 38.16% | 37.19% | 42.28% | 37.78% | 36.69% | 36.92% |
D&A For EBITDA | 67.52 | 67.9 | 69.42 | 53.76 | 53.05 | 42.33 |
EBIT | 455.43 | 436.16 | 632.01 | 604.27 | 501.29 | 548.17 |
EBIT Margin | 33.23% | 32.18% | 38.10% | 34.70% | 33.18% | 34.27% |
Effective Tax Rate | 18.93% | 19.35% | 13.51% | 12.04% | 12.22% | 12.54% |
Revenue as Reported | 1,371 | 1,356 | 1,659 | 1,742 | - | 1,599 |
Advertising Expenses | - | 138.12 | 153.01 | 194.01 | 200.07 | 186.98 |